

BSE SENSEX

83,443

S&amp;P CNX

25,461



#### Stock Info

Bloomberg	SRF IN
Equity Shares (m)	296
M.Cap.(INRb)/(USDb)	960.2 / 11.2
52-Week Range (INR)	3290 / 2127
1, 6, 12 Rel. Per (%)	2/33/30
12M Avg Val (INR M)	1833
Free float (%)	49.7

#### Financials Snapshot (INR b)

Y/E MARCH	2025	2026E	2027E
Sales	146.9	171.1	202.7
EBITDA	28.4	37.4	48.9
Adj. PAT	13.7	20.3	28.4
EBITDA margin (%)	19.3	21.9	24.1
Cons. Adj. EPS (INR)	46.1	68.3	95.5
EPS Gr. (%)	(3.0)	48.4	39.7
BV/Sh. (INR)	424	476	554
<b>Ratios</b>			
Net D:E	0.3	0.3	0.2
RoE (%)	11.4	15.2	18.5
RoCE (%)	9.6	12.7	15.3
Payout (%)	35.7	24.9	17.8
<b>Valuations</b>			
P/E (x)	70.4	47.5	34.0
EV/EBITDA (x)	35.3	26.8	20.5
Div. Yield (%)	0.5	0.5	0.5
FCF Yield (%)	1.2	0.7	0.8

#### Shareholding Pattern (%)

As On	Mar-25	Dec-24	Mar-24
Promoter	50.3	50.3	50.3
DII	18.5	17.8	16.0
FII	18.3	18.4	19.1
Others	13.0	13.6	14.6

FII includes depository receipts

**CMP: INR3,239      TP: INR3,700 (+14%)**
**Buy**

#### Recovery complete; poised for growth in FY26

After a subdued performance in FY24, SRF witnessed a healthy recovery in FY25 across all segments. Moreover, the company expects to sustain the growth momentum going forward.

- In FY25, EBITDA grew ~7% YoY to INR28.3b, driven by growth in Chemicals (up 5%) and Performance Films & Foils (PFF) (up 45%), while Technical Textiles (TTB) saw a decline (down ~8%). Although its margin performance remained mixed across segments, SRF achieved a healthy recovery in all businesses.
- Capex at ~INR11b was lower than the company's initial guidance of INR22-23b. The chemicals business continued to be the largest part of the capex (~62%). In FY26, SRF plans to increase capex intensity and has guided for capex of INR22-23b.
- SRF's moat lies in its technological innovation and advancement to meet evolving customer needs and maintain a leadership position. Its R&D spending has increased at ~11% CAGR over the last decade, with INR1.5b spent in FY25 — around 5.4% of EBITDA.
- With a healthy recovery in FY25, the company is expected to sustain its growth trajectory as its chemical business is estimated to grow ~20% YoY in FY26 led by fluorochemicals and specialty chemicals. However, TTB is expected to remain largely flat.

#### Broad-based recovery; margin performance mixed across segments

- SRF recorded a healthy performance in FY25, with revenue/EBITDA increasing ~12%/7% YoY to INR146.9b/INR28.3b. This was largely led by PFF revenue growth of ~24% to INR55.5b, followed by Chemicals business (6%) and TTB (7%). EBITDA for Chemicals/PFF grew 5%/45% YoY, while TTB reported a decline of 8.5% YoY.
- Chemicals** business witnessed a recovery in FY25 and accounted for 46%/71% of consolidated sales/EBIT. Revenue/EBITDA grew 6%/5% YoY, led by a recovery in specialty chemicals and fluorochemicals. EBITDA margin contracted by ~40bp YoY to 31.9%, led by pricing pressure from Chinese competitors, increased competition and oversupply in domestic chloromethanes.
- Specialty Chemicals'** agro business showed signs of recovery, led by a pickup in demand for key agro intermediates and the stabilization in raw material prices. However, pricing pressure from China continued to drive price adjustments for several products. Accordingly, revenue grew 3% YoY to INR37.9b in this business.
- Fluorochemicals** business also showed recovery with revenue growth of 6% YoY to INR22.5b, led by rising demand for refrigerants due to increased AC and automobile production in India, healthy demand for Dymel, and improvement in Polytetrafluoroethylene (PTFE).

- **PFF business** (~38%/~16% of consolidated revenue/EBIT) delivered healthy growth in FY25, driven by the identification of new export customers in the US and Europe and higher volumes in BOPET and BOPP. Revenue/EBITDA grew 24%/45% YoY (on a lower base) to INR55.5b/INR5.9b.
- **TTB** (14%/10% of consolidated revenue/ EBIT) reported revenue growth of 7% YoY to ~INR20b, led by the highest-ever production and sales of tyre cord fabrics and polyester industrial yarn. However, it reported an EBITDA decline of 8.5% YoY, led by lower margins in the nylon tyre cord fabrics, weak demand and increased competition from low-cost Chinese imports in belting fabrics.
- Other businesses, which include **Coated and Laminated Fabrics** businesses, declined 8.1% to INR43b, led by competition from cheap imports from China.

### Growth supported by upcoming capacity additions

- Over the past few years, SRF has maintained a robust capex program aimed at expanding its manufacturing capabilities and entering new markets. However, its capex investments have focused on enhancing operational efficiency, upgrading existing equipment, and expanding into new business segments, such as the pharma segment.
- SRF has incurred a cumulative capex of **~INR95.2b** over last five years as of Mar'25. Chemicals accounted for the highest capex (~67%), followed by Packaging Films (24%), and TTB (7%).
- The **intensity of capex slowed in FY25**, led by weakness across businesses and SRF's conscious decision to preserve cash. SRF incurred a capex of **INR10.9b in FY25**, down 53% YoY, of which 62% was incurred in the Chemicals business (vs. 70% in FY24), followed by TTB (20% vs. 9% in FY24) and PFF business (16% vs. 19% in FY24).
- The company is focusing on both greenfield (new facilities) and brownfield (expansions/upgrades of existing facilities) projects across its segments.
- Its debottlenecking projects over the past 18 months have resulted in an increase in the chemicals business' overall capacity by **~30%**.
- **Fluorochemicals business:** The company has already announced a capex of INR5.5b for three new fluoropolymers, e.g., Polyvinylidene Fluoride (PTFE), Fluorinated Ethylene Propylene (FEP), and Fluorine Kautschuk Material (FKM), which may be commercialized and completed during FY26.
- **With an improving business scenario in Chemicals, SRF is likely to increase its capex intensity in FY26, in line with its aspirations for the future.**
- In the **PFF business**, SRF approved establishment of a new manufacturing facility for the Bopp-BOPET film line in Indore with an estimated cost of INR4.5b, with operations expected to commence in approximately 25 months.
- **SRF is expecting a total capex of ~INR22-23b in FY26.**

### Increasing investments in R&D

- Through its Chemicals Technology Group (CTG), SRF prioritizes continuous technological innovation and advancement to meet evolving customer needs and maintain a leadership position.
- The company also focuses on process enhancements to reduce its resources, improve cost-effectiveness, and strengthen the value chain by integrating critical raw materials in-house. Management also aims to automate processes to improve robustness, cost, and safety.
- SRF spent ~INR1.5b on R&D in FY25, registering ~11% CAGR over the last decade. R&D spending as a percentage of EBITDA/sales largely remained flat at **5.4%/1%** vs. 5.5%/1.1% in FY24.
- The company has so far filed 481 patents as of FY25 (filed 38 patents in FY25), out of which 151 total patents have been granted (two granted in FY25), indicating its commitment to technological advancement and maintaining a competitive edge in the market.
- In FY25, SRF **launched eight new products** catering to the agrochemical and pharma sectors, while it launched **12 new products in BOPET and BOPP**. These products have good long-term prospects, are at a different maturity level of market potential, and have future growth potential.

### Chemicals and PFF businesses to drive growth

- SRF is expecting a better performance in FY26, led by a strong order book in the specialty business, the ramp-up of export volumes, and growth in PTFE within the fluorochemicals business. The packaging business should improve in the near term, led by increasing focus on high-impact VAPs.
- Over the last decade, SRF has delivered a CAGR of **12%/15%/16%** in revenue/EBITDA/adj. PAT, and we expect a CAGR of 18%/32%/46% over FY25-27. This growth will be largely propelled by the Chemicals business (25% CAGR over FY25-27), followed by Packaging (14%), and TTB (8%).
- The Chemicals business has recorded a CAGR of 18%/18% in revenue/EBITDA over the last decade. Management expects the **business to grow by ~20% YoY in FY26**.
- The **fluorochemicals** segment has posted a 19% CAGR over the last decade, with 6% growth in FY25. Management expects **growth to continue in FY26**, aided by the growing Indian air conditioner industry, the ramp-up in PTFE and healthy demand for Dymel. Pricing pressures are anticipated to ease with market stabilization. SRF will focus on ramping up the newly commissioned plants to meet the rising demand, along with ongoing investments in R&D and technology to introduce the new and enhanced products. **We expect a 28% CAGR in revenue of this business over FY25-27.**
- **Specialty Chemicals business** has recorded a healthy 20% revenue CAGR over the last decade, though it faced macro headwinds in FY25. The business will continue to focus on agrochemicals and pharmaceuticals segments, collaborating with global innovators to drive process development, commercialization, and the production of complex, innovative molecules. **We expect this segment to post a strong 26% CAGR over FY25-27.**

- **TTB** segment has not been able to move the needle materially over the last decade, with a flat CAGR. SRF expects a similar performance in FY26 as in FY25. **We expect a CAGR of 8%/28% in revenue/EBITDA over FY25-27.**
- **PFF business** posted a 16% CAGR over the past decade, with strong growth of 24% in FY25. BOPET capacity utilization in India is expected to be better going forward, while BOPP capacity utilization may witness some pressure due to the addition of new lines during the year. **With the temporary closure of Jindal Poly's manufacturing facility in Nashik due to fire outbreak, SRF's packaging business is expected to benefit from the increased supply gap in the industry.** In FY26, SRF's primary focus will be on significantly increasing sales of high-impact products across BOPP and BOPET with the commissioning of new downstream assets, including new offline coating machines in India and metallizers in Thailand and India. **We expect a CAGR of 14%/36% in revenue/EBITDA for this business over FY25-27.**

#### Broad-based improvement across key financial metrics

- SRF's net working capital cycle improved marginally to 56 from 55 in FY24. This improvement was driven by a **decline in receivables/inventory days by 1/14**, bringing them down to **51/111 days**. However, this gain was partially offset by a **13-day reduction in payables to 107 days**.
- Although there was a marginal decline in gross margin/EBITDA margin to 48%/19% from 49%/20% in FY24, gross profit/EBITDA rose 9%/~7% to INR70b/INR28b.
- The company reported a **19% YoY increase** in cash flow from operations (CFO) to **INR24.9b** in FY25. This marked a strong turnaround from the 28% decline in FY24. As a result, the CFO/EBITDA ratio improved to 88% from 79% in FY24. Further, FCF improved to INR12b from an outflow of INR1.8b in FY24.
- SRF's debt-to-equity ratio **improved to 0.37x** from 0.43x in FY24, reflecting a healthier balance sheet. This was driven by an increase in profitability and a reduction in long-term borrowings.

#### Valuation and view


- Considering a healthy recovery in FY25, SRF aims to maintain the growth trajectory in FY26, driven by strategic investments and capacity expansions. The company targets to improve the performance of all segments, focusing on market recovery, innovation, and operational efficiencies to sustain profitability.
- Chemicals business (fluorochemicals and specialty chemicals) is expected to grow 20% YoY in FY26E, led by the ramp-up of commissioned facilities. Its packaging business is likely to continue its growth trajectory, led by the ramp-up in sales of high-impact VAPs and aluminum foils. TTB is expected to witness flat growth in FY26E.
- We expect SRF to clock a CAGR of 12%/15%/16% in revenue/EBITDA/adj. PAT over FY25-27. **We reiterate our BUY rating on the stock with our SoTP-based TP of INR3,700, owing to its rich valuations.**

## Exhibit 1: Valuation methodology


EV/EBITDA	FY26 EBITDA (INR m)	Multiple (x)	EV (INR m)
TTB	4,759	12	59,253
Chemicals	35,928	25	9,13,469
Packaging Films	10,886	12	1,35,317
Others	1,154	10	12,006
Less: other income/unallocable	3,423	10	34,230
<b>Total EV</b>			<b>10,85,815</b>
Less: Debt			52,412
Less: Minority Interest			-
Add: Cash & Cash Equivalents			7,639
<b>Target Mcap (INR m)</b>			<b>10,41,042</b>
Outstanding share (m)			297.4
<b>Target Price (INR)</b>			<b>3,500</b>

Source: MOFSL

## Exhibit 2: One-year forward P/E ratio



## Exhibit 3: One-year forward EV/EBITDA ratio




## Story in charts

### Exhibit 4: Summary of FY25 performance and outlook

Business Segment	TTB	Chemicals Business		Packaging Films Business
		Fluorochemicals	Specialty Chemicals	
<b>Revenue in FY25 (INR b)</b>	<b>20.3</b>	<b>22.5</b>	<b>37.9</b>	<b>55.5</b>
Growth %	6.9	5.5	3.5	23.7
CAGR % (FY15-25)	-0.1	18.6	20.0	16.1
CAGR % (FY25-27E)	8.5	27.7	26.3	14.4
<b>EBITDA (INR b)</b>	<b>2.9</b>	<b>21.3</b>		<b>5.9</b>
EBITDA M %	14	32		11
CAGR % (FY15-25)	1	18		18
CAGR % (FY25-27E)	28	30		36
Current Situation	❖ Aggressive import prices for BF from China continue to effect margins	❖ Mandate for in-cabin AC for Commercial vehicles expected to further drive ref gas consumption	❖ Pricing pressure from Chinese competitors continued, leading to price adjustments for multiple products	❖ Demand-supply balance for BOPP better than BOPET. Capacity utilization in India improved for both BOPP and BOPET
Key Developments	❖ Achieved highest-ever production and sales in FY'25 of Tyre Cord Fabrics, Polyester Industrial Yarn and Belting Fabrics	❖ AHF-3 plant capitalized; to enhance HFC output leveraging the quota regime. PTFE showed signs of improvement; full ramp-up expected in FY'26	❖ Successfully launched 5 new agro products and 3 new pharma products in FY'25	❖ Maintained strong international momentum with improved market share in South Africa and sales growth in mainland Europe. Margin pressure in Thailand continues due to cheap imports
Outlook	❖ Demand for NTCF likely to be stable. Focus on high-end VAPs in BF and expanded capacity to be the future growth drivers	❖ New HF plant commissioned; to support costs and higher volumes of ref gases in FY'26. CMS demand and prices to remain range bound; creating export ability to offset pricing pressure	❖ Launch of new pharma intermediates as well as ramp up of recently commissioned facilities to drive growth. Focus on cost structures and efficiency enhancement to counterbalance pricing pressure	❖ Ongoing demand-supply imbalance in BOPET expected to improve in medium term. Continue ramp-up in sales of high-impact VAPs in both BOPET and BOPP


Source: MOFSL

### Exhibit 5: SRF's consolidated revenue expected to register 18% CAGR over FY25-27




Source: Company, MOFSL

### Exhibit 6: Consolidated EBITDA likely to report 32% CAGR over FY25-27




Source: Company, MOFSL


**Exhibit 7: Consolidated adj. PAT expected to clock 24% CAGR over FY25-27**




**Exhibit 8: Capex trend**




**Exhibit 9: Revenue mix trend**



**Exhibit 10: EBIT mix trend**



**Exhibit 11: Cash flow trend**



**Exhibit 12: Net debt trend**






Exhibit 13: Geography-wise revenue mix (%)



Source: Company, MOFSL


Exhibit 14: RoE and RoCE trends




Source: Company, MOFSL

## Key Charts


**Exhibit 15: Chemicals' revenue likely to continue its growth momentum over FY25-27**




**Exhibit 16: Chemicals' EBIT margin trend**




**Exhibit 17: Fluorochemicals & Ref gas revenue trend (INR b)**



**Exhibit 18: Specialty Chemicals' revenue trend (INR b)**




**Exhibit 19: Chloromethane's revenue trend (INR b)**




**Exhibit 20: SRF's Fluorochemicals – business products**


Source: Company, MOFSL

**Exhibit 21: PFF revenue to register 14% CAGR over FY25-27**


Source: Company, MOFSL

**Exhibit 22: PFF business EBIT trend**


Source: Company, MOFSL

**Exhibit 23: PPF business RoCE trajectory**

Source: Company, MOFSL

**Exhibit 24: TTB revenue to clock 8% CAGR over FY25-27**

Source: Company, MOFSL

**Exhibit 25: TTB EBIT margin trend**

Source: Company, MOFSL

## Financials and valuations

Consolidated - Income Statement									(INRm)
Y/E March	FY19	FY20	FY21	FY22	FY23	FY24	FY25	FY26E	FY27E
Income from Operations	70,996	72,094	84,000	1,24,337	1,48,703	1,31,385	1,46,931	1,71,071	2,02,654
Less: Excise Duty	0	0	0	0	0	0	0	0	0
<b>Total Income from Operations</b>	<b>70,996</b>	<b>72,094</b>	<b>84,000</b>	<b>1,24,337</b>	<b>1,48,703</b>	<b>1,31,385</b>	<b>1,46,931</b>	<b>1,71,071</b>	<b>2,02,654</b>
Change (%)	27.0	1.5	16.5	48.0	19.6	-11.6	11.8	16.4	18.5
Cost of Materials Consumed	39,671	36,870	40,189	60,669	73,935	67,088	76,992	87,554	1,01,042
Personnel Expenses	4,608	5,419	6,214	7,800	8,138	9,350	10,425	11,120	12,767
Other Expenses	13,508	15,221	16,264	24,835	30,297	28,339	31,138	34,998	39,947
<b>Total Expenditure</b>	<b>57,787</b>	<b>57,510</b>	<b>62,667</b>	<b>93,305</b>	<b>1,12,371</b>	<b>1,04,777</b>	<b>1,18,555</b>	<b>1,33,672</b>	<b>1,53,756</b>
<b>EBITDA</b>	<b>13,209</b>	<b>14,584</b>	<b>21,333</b>	<b>31,032</b>	<b>36,332</b>	<b>26,608</b>	<b>28,376</b>	<b>37,399</b>	<b>48,898</b>
Margin (%)	18.6	20.2	25.4	25.0	24.4	20.3	19.3	21.9	24.1
Depreciation	3,582	3,886	4,531	5,172	5,753	6,726	7,715	8,443	9,619
<b>EBIT</b>	<b>9,627</b>	<b>10,698</b>	<b>16,803</b>	<b>25,860</b>	<b>30,579</b>	<b>19,882</b>	<b>20,661</b>	<b>28,956</b>	<b>39,279</b>
Int. and Finance Charges	1,984	2,007	1,340	1,159	2,048	3,023	3,760	3,556	3,424
Other Income	280	491	545	428	749	830	1,327	1,526	1,755
<b>PBT bef. EO Exp.</b>	<b>7,923</b>	<b>9,182</b>	<b>16,008</b>	<b>25,128</b>	<b>29,280</b>	<b>17,689</b>	<b>18,229</b>	<b>26,927</b>	<b>37,610</b>
EO Items	262	997	116	727	-1,040	-767	-1,192	0	0
<b>PBT after EO Exp.</b>	<b>8,185</b>	<b>10,179</b>	<b>16,123</b>	<b>25,856</b>	<b>28,240</b>	<b>16,922</b>	<b>17,037</b>	<b>26,927</b>	<b>37,610</b>
Current Tax	1,769	265	4,154	7,139	6,617	3,565	4,544	6,598	9,215
Deferred Tax	0	-277	-10	-173	0	0	-14	0	0
Tax Rate (%)	21.6	-0.1	25.7	26.9	23.4	21.1	26.6	24.5	24.5
<b>Reported PAT</b>	<b>6,416</b>	<b>10,191</b>	<b>11,979</b>	<b>18,889</b>	<b>21,623</b>	<b>13,357</b>	<b>12,508</b>	<b>20,329</b>	<b>28,394</b>
<b>Adjusted PAT</b>	<b>6,155</b>	<b>9,194</b>	<b>11,864</b>	<b>18,162</b>	<b>22,663</b>	<b>14,124</b>	<b>13,700</b>	<b>20,329</b>	<b>28,394</b>
Change (%)	48.2	49.4	29.0	53.1	24.8	-37.7	-3.0	48.4	39.7
Margin (%)	8.7	12.8	14.1	14.6	15.2	10.8	9.3	11.9	14.0

Consolidated - Balance Sheet									(INRm)
Y/E March	FY19	FY20	FY21	FY22	FY23	FY24	FY25	FY26E	FY27E
Equity Share Capital	575	585	603	2,974	2,974	2,974	2,974	2,974	2,974
Total Reserves	40,718	48,748	67,962	82,679	1,00,296	1,11,816	1,23,288	1,38,560	1,61,898
<b>Net Worth</b>	<b>41,293</b>	<b>49,333</b>	<b>68,564</b>	<b>85,654</b>	<b>1,03,271</b>	<b>1,14,790</b>	<b>1,26,262</b>	<b>1,41,534</b>	<b>1,64,872</b>
Deferred Liabilities	3,420	1,755	3,862	6,775	8,092	9,387	10,553	10,553	10,553
Total Loans	37,302	40,468	33,950	35,394	43,541	49,202	46,412	48,412	49,412
<b>Capital Employed</b>	<b>82,014</b>	<b>91,556</b>	<b>1,06,376</b>	<b>1,27,822</b>	<b>1,54,903</b>	<b>1,73,380</b>	<b>1,83,227</b>	<b>2,00,500</b>	<b>2,24,838</b>
Gross Block	68,322	76,934	96,167	1,06,943	1,28,622	1,67,373	1,80,146	2,00,146	2,33,146
Less: Accum. Deprn.	12,269	15,540	20,071	25,243	30,997	37,723	45,438	53,880	63,499
<b>Net Fixed Assets</b>	<b>56,053</b>	<b>61,394</b>	<b>76,096</b>	<b>81,699</b>	<b>97,626</b>	<b>1,29,650</b>	<b>1,34,708</b>	<b>1,46,266</b>	<b>1,69,646</b>
Goodwill on Consolidation	41	6	6	0	0	0	0	0	0
Capital WIP	7,536	13,933	7,723	16,716	24,055	8,053	8,110	11,110	6,110
Current Investments	1,005	1,985	4,125	3,167	4,901	4,056	7,045	7,045	7,045
<b>Total Investments</b>	<b>1,006</b>	<b>2,027</b>	<b>4,167</b>	<b>3,209</b>	<b>4,942</b>	<b>5,267</b>	<b>8,273</b>	<b>8,273</b>	<b>8,273</b>
<b>Curr. Assets, Loans&amp;Adv.</b>	<b>34,243</b>	<b>31,265</b>	<b>41,121</b>	<b>56,025</b>	<b>60,735</b>	<b>61,574</b>	<b>64,123</b>	<b>70,331</b>	<b>81,272</b>
Inventory	12,247	12,012	14,658	21,385	22,743	23,265	23,490	25,907	29,897
Account Receivables	10,288	8,911	12,746	17,925	17,856	19,428	21,695	23,434	27,761
Cash and Bank Balance	1,989	1,255	2,820	4,594	6,165	4,075	3,538	3,279	3,246
Loans and Advances	9,719	9,088	10,898	12,123	13,972	14,805	15,401	17,711	20,368
<b>Curr. Liability &amp; Prov.</b>	<b>16,865</b>	<b>17,211</b>	<b>22,918</b>	<b>29,944</b>	<b>32,642</b>	<b>31,440</b>	<b>32,344</b>	<b>35,837</b>	<b>40,821</b>
Account Payables	13,824	11,117	15,852	20,964	22,313	21,978	23,316	25,907	29,897
Other Current Liabilities	2,600	5,653	6,544	8,391	9,642	8,660	8,104	8,914	9,806
Provisions	441	442	522	590	687	802	924	1,017	1,118
<b>Net Current Assets</b>	<b>17,378</b>	<b>14,054</b>	<b>18,203</b>	<b>26,081</b>	<b>28,093</b>	<b>30,134</b>	<b>31,779</b>	<b>34,494</b>	<b>40,451</b>
Deferred Tax assets	0	143	181	116	187	276	357	357	357
<b>Appl. of Funds</b>	<b>82,014</b>	<b>91,556</b>	<b>1,06,376</b>	<b>1,27,822</b>	<b>1,54,903</b>	<b>1,73,380</b>	<b>1,83,227</b>	<b>2,00,500</b>	<b>2,24,838</b>

## Financials and valuations

### Ratios

Y/E March	FY19	FY20	FY21	FY22	FY23	FY24	FY25	FY26E	FY27E
<b>Basic (INR)</b>									
EPS	<b>20.7</b>	<b>30.9</b>	<b>39.9</b>	<b>61.1</b>	<b>76.2</b>	<b>47.5</b>	<b>46.1</b>	<b>68.3</b>	<b>95.5</b>
Cash EPS	32.7	44.0	55.1	78.5	95.5	70.1	72.0	96.7	127.8
BV/Share	138.8	165.9	230.5	288.0	347.2	385.9	424.5	475.8	554.3
DPS	3.9	2.8	4.9	16.8	7.2	7.2	15.0	17.0	17.0
Payout (%)	20.8	9.6	12.1	26.4	9.9	16.0	35.7	24.9	17.8
<b>Valuation (x)</b>									
P/E	156.7	105	81	53	43	68	70	47	34
Cash P/E	99.1	74	59	41	34	46	45	34	25
P/BV	23.4	20	14	11	9	8	8	7	6
EV/Sales	14.1	14	12	8	7	8	7	6	5
EV/EBITDA	75.6	69	46	32	27	38	35	27	21
Dividend Yield (%)	0.1	0.1	0.1	0.5	0.2	0.2	0.5	0.5	0.5
FCF per share	-5.3	-2.3	19.1	9.7	0.0	-6.1	40.5	21.4	25.0
<b>Return Ratios (%)</b>									
RoE	16.0	20.3	20.1	23.6	24.0	13.0	11.4	15.2	18.5
RoCE	10.7	13.3	13.4	17.2	17.9	10.5	9.6	12.7	15.3
RoIC	18.0	15.3	26.3	34.2	34.7	18.2	17.4	22.2	26.5
<b>Working Capital Ratios</b>									
Fixed Asset Turnover (x)	1.0	0.9	0.9	1.2	1.2	0.8	0.8	0.9	0.9
Asset Turnover (x)	0.9	0.8	0.8	1.0	1.0	0.8	0.8	0.9	0.9
Inventory (Days)	113	119	133	129	112	127	111	108	108
Debtor (Days)	53	45	55	53	44	54	54	50	50
Creditor (Days)	127	110	144	126	110	120	111	108	108
Working Cap. Turnover (Days)	79	65	67	63	54	72	70	67	67
<b>Leverage Ratio (x)</b>									
Current Ratio	2.0	1.8	1.8	1.9	1.9	2.0	2.0	2.0	2.0
Interest Cover Ratio	5	5	13	22	15	7	5	8	11
Debt/Equity	0.9	0.8	0.5	0.4	0.4	0.4	0.4	0.3	0.3

### Consolidated - Cash Flow Statement

Y/E March	FY19	FY20	FY21	FY22	FY23	FY24	FY25	FY26E	FY27E
(INRm)									
OP/(Loss) before Tax	8,269	10,706	16,099	25,856	28,240	16,922	17,037	26,927	37,610
Depreciation	3,669	3,929	4,531	5,172	5,753	6,726	7,715	8,443	9,619
Interest & Finance Charges	2,016	2,016	1,340	1,159	2,048	3,023	3,760	3,556	3,424
Direct Taxes Paid	-1,502	-1,427	-2,553	-4,016	-6,617	-3,565	-4,544	-6,598	-9,215
(Inc)/Dec in WC	-3,165	-239	-1,236	-6,645	-408	-2,168	906	-2,973	-5,990
<b>CF from Operations</b>	<b>9,286</b>	<b>14,984</b>	<b>18,181</b>	<b>21,527</b>	<b>29,017</b>	<b>20,938</b>	<b>24,875</b>	<b>29,354</b>	<b>35,447</b>
Others	-330	-1,940	-464	-469	0	0	0	0	0
<b>CF from Operating incl EO</b>	<b>8,956</b>	<b>13,044</b>	<b>17,717</b>	<b>21,057</b>	<b>29,017</b>	<b>20,938</b>	<b>24,875</b>	<b>29,354</b>	<b>35,447</b>
(inc)/dec in FA	-10,526	-13,730	-12,047	-18,171	-29,019	-22,748	-12,830	-23,000	-28,000
<b>Free Cash Flow</b>	<b>-1,570</b>	<b>-685</b>	<b>5,670</b>	<b>2,886</b>	<b>-2</b>	<b>-1,810</b>	<b>12,044</b>	<b>6,354</b>	<b>7,447</b>
(Pur)/Sale of Investments	332	-886	-1,886	1,028	-1,733	-325	-3,006	0	0
Others	53	2,813	-1,064	1,265	1,138	800	996	0	0
<b>CF from Investments</b>	<b>-10,142</b>	<b>-11,803</b>	<b>-14,997</b>	<b>-15,877</b>	<b>-29,614</b>	<b>-22,273</b>	<b>-14,840</b>	<b>-23,000</b>	<b>-28,000</b>
Issue of Shares	1	0	7,500	2	0	0	0	0	0
Inc/(Dec) in Debt	2,677	3,205	-6,856	622	8,147	5,662	-2,790	2,000	1,000
Interest Paid	-2,241	-2,040	-1,574	-1,173	-2,048	-3,023	-3,760	-3,556	-3,424
Dividend Paid	-836	-803	-1,408	-2,117	-2,142	-2,142	-4,462	-5,056	-5,056
Others	2,606	-2,337	1,182	-741	-1,789	-1,252	439	0	0
<b>CF from Fin. Activity</b>	<b>2,207</b>	<b>-1,975</b>	<b>-1,155</b>	<b>-3,406</b>	<b>2,168</b>	<b>-754</b>	<b>-10,572</b>	<b>-6,612</b>	<b>-7,480</b>
<b>Inc/Dec of Cash</b>	<b>1,021</b>	<b>-734</b>	<b>1,565</b>	<b>1,774</b>	<b>1,571</b>	<b>-2,089</b>	<b>-538</b>	<b>-258</b>	<b>-33</b>
Opening Balance	967	1,989	1,255	2,820	4,594	6,164	4,075	3,538	3,279
<b>Closing Balance</b>	<b>1,989</b>	<b>1,255</b>	<b>2,820</b>	<b>4,594</b>	<b>6,164</b>	<b>4,075</b>	<b>3,538</b>	<b>3,279</b>	<b>3,246</b>

Investment in securities market are subject to market risks. Read all the related documents carefully before investing

Explanation of Investment Rating	
Investment Rating	Expected return (over 12-month)
BUY	>=15%
SELL	< - 10%
NEUTRAL	< - 10 % to 15%
UNDER REVIEW	Rating may undergo a change
NOT RATED	We have forward looking estimates for the stock but we refrain from assigning recommendation

\*In case the recommendation given by the Research Analyst is inconsistent with the investment rating legend for a continuous period of 30 days, the Research Analyst shall be within following 30 days take appropriate measures to make the recommendation consistent with the investment rating legend.

#### Disclosures

The following Disclosures are being made in compliance with the SEBI Research Analyst Regulations 2014 (herein after referred to as the Regulations). Motilal Oswal Financial Services Ltd. (MOFSL) is a SEBI Registered Research Analyst having registration no. INH000000412. MOFSL, the Research Entity (RE) as defined in the Regulations, is engaged in the business of providing Stock broking services, Depository participant services & distribution of various financial products. MOFSL is a listed public company, the details in respect of which are available on [www.motilaloswal.com](http://www.motilaloswal.com). MOFSL (erstwhile Motilal Oswal Securities Limited - MOSL) is registered with the Securities & Exchange Board of India (SEBI) and is a registered Trading Member with National Stock Exchange of India Ltd. (NSE) and Bombay Stock Exchange Limited (BSE), Multi Commodity Exchange of India Limited (MCX) and National Commodity & Derivatives Exchange Limited (NCDEX) for its stock broking activities & is Depository participant with Central Depository Services Limited (CDSL) National Securities Depository Limited (NSDL), NERL, COMRIS and CCRL and is member of Association of Mutual Funds of India (AMFI) for distribution of financial products and Insurance Regulatory & Development Authority of India (IRDA) as Corporate Agent for insurance products. Details of associate entities of Motilal Oswal Financial Services Limited are available on the website at <http://onlinereports.motilaloswal.com/Dormant/documents/List%20of%20Associate%20companies.pdf>

MOFSL and its associate company(ies), their directors and Research Analyst and their relatives may; (a) from time to time, have a long or short position in, act as principal in, and buy or sell the securities or derivatives thereof of companies mentioned herein. (b) be engaged in any other transaction involving such securities and earn brokerage or other compensation or act as a market maker in the financial instruments of the company(ies) discussed herein or act as an advisor or lender/borrower to such company(ies) or may have any other potential conflict of interests with respect to any recommendation and other related information and opinions.; however the same shall have no bearing whatsoever on the specific recommendations made by the analyst(s), as the recommendations made by the analyst(s) are completely independent of the views of the associates of MOFSL even though there might exist an inherent conflict of interest in some of the stocks mentioned in the research report.

MOFSL and / or its affiliates do and seek to do business including investment banking with companies covered in its research reports. As a result, the recipients of this report should be aware that MOFSL may have a potential conflict of interest that may affect the objectivity of this report. Compensation of Research Analysts is not based on any specific merchant banking, investment banking or brokerage service transactions. Details of pending Enquiry Proceedings of Motilal Oswal Financial Services Limited are available on the website at <https://galaxy.motilaloswal.com/ResearchAnalyst/PublishViewLitigation.aspx>

A graph of daily closing prices of securities is available at [www.nseindia.com](http://www.nseindia.com), [www.bseindia.com](http://www.bseindia.com). Research Analyst views on Subject Company may vary based on Fundamental research and Technical Research. Proprietary trading desk of MOFSL or its associates maintains arm's length distance with Research Team as all the activities are segregated from MOFSL research activity and therefore it can have an independent view with regards to Subject Company for which Research Team have expressed their views.

#### Regional Disclosures (outside India)

This report is not directed or intended for distribution to or use by any person or entity resident in a state, country or any jurisdiction, where such distribution, publication, availability or use would be contrary to law, regulation or which would subject MOFSL & its group companies to registration or licensing requirements within such jurisdictions.

#### For Hong Kong:

This report is distributed in Hong Kong by Motilal Oswal capital Markets (Hong Kong) Private Limited, a licensed corporation (CE AYY-301) licensed and regulated by the Hong Kong Securities and Futures Commission (SFC) pursuant to the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong) "SFO". As per SEBI (Research Analyst Regulations) 2014 Motilal Oswal Securities (SEBI Reg. No. INH000000412) has an agreement with Motilal Oswal capital Markets (Hong Kong) Private Limited for distribution of research report in Hong Kong. This report is intended for distribution only to "Professional Investors" as defined in Part I of Schedule 1 to SFO. Any investment or investment activity to which this document relates is only available to professional investor and will be engaged only with professional investors." Nothing here is an offer or solicitation of these securities, products and services in any jurisdiction where their offer or sale is not qualified or exempt from registration. The Indian Analyst(s) who compile this report is/are not located in Hong Kong & are not conducting Research Analysis in Hong Kong.

#### For U.S.

Motilal Oswal Financial Services Limited (MOFSL) is not a registered broker - dealer under the U.S. Securities Exchange Act of 1934, as amended (the "1934 act") and under applicable state laws in the United States. In addition MOFSL is not a registered investment adviser under the U.S. Investment Advisers Act of 1940, as amended (the "Advisers Act" and together with the 1934 Act, the "Acts), and under applicable state laws in the United States. Accordingly, in the absence of specific exemption under the Acts, any brokerage and investment services provided by MOFSL, including the products and services described herein are not available to or intended for U.S. persons. This report is intended for distribution only to "Major Institutional Investors" as defined by Rule 15a-6(b)(4) of the Exchange Act and interpretations thereof by SEC (henceforth referred to as "major institutional investors"). This document must not be acted on or relied on by persons who are not major institutional investors. Any investment or investment activity to which this document relates is only available to major institutional investors and will be engaged in only with major institutional investors. In reliance on the exemption from registration provided by Rule 15a-6 of the U.S. Securities Exchange Act of 1934, as amended (the "Exchange Act") and interpretations thereof by the U.S. Securities and Exchange Commission ("SEC") in order to conduct business with Institutional Investors based in the U.S., MOFSL has entered into a chaperoning agreement with a U.S. registered broker-dealer, Motilal Oswal Securities International Private Limited. ("MOSIPL"). Any business interaction pursuant to this report will have to be executed within the provisions of this chaperoning agreement.

The Research Analysts contributing to the report may not be registered /qualified as research analyst with FINRA. Such research analyst may not be associated persons of the U.S. registered broker-dealer, MOSIPL, and therefore, may not be subject to NASD rule 2711 and NYSE Rule 472 restrictions on communication with a subject company, public appearances and trading securities held by a research analyst account.

#### For Singapore

In Singapore, this report is being distributed by Motilal Oswal Capital Markets (Singapore) Pte. Ltd. ("MOCMSPL") (UEN 201129401Z), which is a holder of a capital markets services license and an exempt financial adviser in Singapore. This report is distributed solely to persons who (a) qualify as "institutional investors" as defined in section 4A(1)(c) of the Securities and Futures Act of Singapore ("SFA") or (b) are considered "accredited investors" as defined in section 2(1) of the Financial Advisers Regulations of Singapore read with section 4A(1)(a) of the SFA. Accordingly, if a recipient is neither an "institutional investor" nor an "accredited investor", they must immediately discontinue any use of this Report and inform MOCMSPL. In respect of any matter arising from or in connection with the research you could contact the following representatives of MOCMSPL. In case of grievances for any of the services rendered by MOCMSPL write to [grievances@motilaloswal.com](mailto:grievances@motilaloswal.com).

Nainesh Rajani

Email: [nainesh.rajani@motilaloswal.com](mailto:nainesh.rajani@motilaloswal.com)

Contact: (+65) 8328 0276

#### Specific Disclosures

1. Research Analyst and/or his/her relatives do not have a financial interest in the subject company(ies), as they do not have equity holdings in the subject company(ies).  
MOFSL has financial interest in the subject company(ies) at the end of the week immediately preceding the date of publication of the Research Report: Yes.  
Nature of Financial interest is holding equity shares or derivatives of the subject company
2. Research Analyst and/or his/her relatives do not have actual/beneficial ownership of 1% or more securities in the subject company(ies) at the end of the month immediately preceding the date of publication of Research Report.  
MOFSL has actual/beneficial ownership of 1% or more securities of the subject company(ies) at the end of the month immediately preceding the date of publication of Research Report: No
3. Research Analyst and/or his/her relatives have not received compensation/other benefits from the subject company(ies) in the past 12 months.  
MOFSL may have received compensation from the subject company(ies) in the past 12 months.
4. Research Analyst and/or his/her relatives do not have material conflict of interest in the subject company at the time of publication of research report.  
MOFSL does not have material conflict of interest in the subject company at the time of publication of research report.
5. Research Analyst has not served as an officer, director or employee of subject company(ies).
6. MOFSL has not acted as a manager or co-manager of public offering of securities of the subject company in past 12 months.
7. MOFSL has not received compensation for investment banking /merchant banking/brokerage services from the subject company(ies) in the past 12 months.

8. MOFSL may have received any compensation for products or services other than investment banking or merchant banking or brokerage services from the subject company(ies) in the past 12 months.
9. MOFSL may have received compensation or other benefits from the subject company(ies) or third party in connection with the research report.
10. MOFSL has not engaged in market making activity for the subject company.

The associates of MOFSL may have:

- financial interest in the subject company
- actual/beneficial ownership of 1% or more securities in the subject company at the end of the month immediately preceding the date of publication of the Research Report or date of the public appearance.
- received compensation/other benefits from the subject company in the past 12 months
- any other potential conflict of interests with respect to any recommendation and other related information and opinions.; however the same shall have no bearing whatsoever on the specific recommendations made by the analyst(s), as the recommendations made by the analyst(s) are completely independent of the views of the associates of MOFSL even though there might exist an inherent conflict of interest in some of the stocks mentioned in the research report.
- acted as a manager or co-manager of public offering of securities of the subject company in past 12 months
- be engaged in any other transaction involving such securities and earn brokerage or other compensation or act as a market maker in the financial instruments of the company(ies) discussed herein or act as an advisor or lender/borrower to such company(ies)
- received compensation from the subject company in the past 12 months for investment banking / merchant banking / brokerage services or from other than said services.
- Served subject company as its clients during twelve months preceding the date of distribution of the research report.

The associates of MOFSL has not received any compensation or other benefits from third party in connection with the research report

Above disclosures include beneficial holdings lying in demat account of MOFSL which are opened for proprietary investments only. While calculating beneficial holdings, It does not consider demat accounts which are opened in name of MOFSL for other purposes (i.e holding client securities, collaterals, error trades etc.). MOFSL also earns DP income from clients which are not considered in above disclosures.

#### Analyst Certification

The views expressed in this research report accurately reflect the personal views of the analyst(s) about the subject securities or issues, and no part of the compensation of the research analyst(s) was, is, or will be directly or indirectly related to the specific recommendations and views expressed by research analyst(s) in this report.

#### Terms & Conditions:

This report has been prepared by MOFSL and is meant for sole use by the recipient and not for circulation. The report and information contained herein is strictly confidential and may not be altered in any way, transmitted to, copied or distributed, in part or in whole, to any other person or to the media or reproduced in any form, without prior written consent of MOFSL. The report is based on the facts, figures and information that are considered true, correct, reliable and accurate. The intent of this report is not recommendatory in nature. The information is obtained from publicly available media or other sources believed to be reliable. Such information has not been independently verified and no guaranty, representation of warranty, express or implied, is made as to its accuracy, completeness or correctness. All such information and opinions are subject to change without notice. The report is prepared solely for informational purpose and does not constitute an offer document or solicitation of offer to buy or sell or subscribe for securities or other financial instruments for the clients. Though disseminated to all the customers simultaneously, not all customers may receive this report at the same time. MOFSL will not treat recipients as customers by virtue of their receiving this report.

#### Disclaimer:

The report and information contained herein is strictly confidential and meant solely for the selected recipient and may not be altered in any way, transmitted to, copied or distributed, in part or in whole, to any other person or to the media or reproduced in any form, without prior written consent. This report and information herein is solely for informational purpose and may not be used or considered as an offer document or solicitation of offer to buy or sell or subscribe for securities or other financial instruments. Nothing in this report constitutes investment, legal, accounting and tax advice or a representation that any investment or strategy is suitable or appropriate to your specific circumstances. The securities discussed and opinions expressed in this report may not be suitable for all investors, who must make their own investment decisions, based on their own investment objectives, financial positions and needs of specific recipient. This may not be taken in substitution for the exercise of independent judgment by any recipient. Each recipient of this document should make such investigations as it deems necessary to arrive at an independent evaluation of an investment in the securities of companies referred to in this document (including the merits and risks involved), and should consult its own advisors to determine the merits and risks of such an investment. The investment discussed or views expressed may not be suitable for all investors. Certain transactions -including those involving futures, options, another derivative products as well as non-investment grade securities - involve substantial risk and are not suitable for all investors. No representation or warranty, express or implied, is made as to the accuracy, completeness or fairness of the information and opinions contained in this document. The Disclosures of Interest Statement incorporated in this document is provided solely to enhance the transparency and should not be treated as endorsement of the views expressed in the report. This information is subject to change without any prior notice. The Company reserves the right to make modifications and alterations to this statement as may be required from time to time without any prior approval. MOFSL, its associates, their directors and the employees may from time to time, effect or have effected an own account transaction in, or deal as principal or agent in or for the securities mentioned in this document. They may perform or seek to perform investment banking or other services for, or solicit investment banking or other business from, any company referred to in this report. Each of these entities functions as a separate, distinct and independent of each other. The recipient should take this into account before interpreting the document. This report has been prepared on the basis of information that is already available in publicly accessible media or developed through analysis of MOFSL. The views expressed are those of the analyst, and the Company may or may not subscribe to all the views expressed therein. This document is being supplied to you solely for your information and may not be reproduced, redistributed or passed on, directly or indirectly, to any other person or published, copied, in whole or in part, for any purpose. This report is not directed or intended for distribution to, or use by, any person or entity who is a citizen or resident of or located in any locality, state, country or other jurisdiction, where such distribution, publication, availability or use would be contrary to law, regulation or which would subject MOFSL to any registration or licensing requirement within such jurisdiction. The securities described herein may or may not be eligible for sale in all jurisdictions or to certain category of investors. Persons in whose possession this document may come are required to inform themselves of and to observe such restriction. Neither the Firm, nor its directors, employees, agents or representatives shall be liable for any damages whether direct or indirect, incidental, special or consequential including lost revenue or lost profits that may arise from or in connection with the use of the information. The person accessing this information specifically agrees to exempt MOFSL or any of its affiliates or employees from, any and all responsibility/liability arising from such misuse and agrees not to hold MOFSL or any of its affiliates or employees responsible for any such misuse and further agrees to hold MOFSL or any of its affiliates or employees free and harmless from all losses, costs, damages, expenses that may be suffered by the person accessing this information due to any errors and delays.

This report is meant for the clients of Motilal Oswal only.

Investment in securities market are subject to market risks. Read all the related documents carefully before investing.

Registration granted by SEBI and certification from NISM in no way guarantee performance of the intermediary or provide any assurance of returns to investors.

Registered Office Address: Motilal Oswal Tower, Rahimtullah Sayani Road, Opposite Parel ST Depot, Prabhadevi, Mumbai-400025; Tel No.: 022 - 71934200 / 71934263; [www.motilaloswal.com](http://www.motilaloswal.com). Correspondence Address: Palm Spring Centre, 2nd Floor, Palm Court Complex, New Link Road, Malad (West), Mumbai- 400 064. Tel No: 022 71881000. Details of Compliance Officer: Neeraj Agarwal, Email Id: [na@motilaloswal.com](mailto:na@motilaloswal.com), Contact No.:022-40548085.

Grievance Redressal Cell:

Contact Person	Contact No.	Email ID
Ms. Hemangi Date	022 40548000 / 022 67490600	<a href="mailto:query@motilaloswal.com">query@motilaloswal.com</a>
Ms. Kumud Upadhyay	022 40548082	<a href="mailto:servicehead@motilaloswal.com">servicehead@motilaloswal.com</a>
Mr. Ajay Menon	022 40548083	<a href="mailto:lam@motilaloswal.com">lam@motilaloswal.com</a>

Registration details of group entities.: Motilal Oswal Financial Services Ltd. (MOFSL): INZ000158836 (BSE/NSE/MCX/NCDEX); CDSL and NSDL: IN-DP-16-2015; Research Analyst: INH000000412 . AMFI: ARN : 146822. IRDA Corporate Agent – CA0579. Motilal Oswal Financial Services Ltd. is a distributor of Mutual Funds, PMS, Fixed Deposit, Insurance, Bond, NCDs and IPO products.

Customer having any query/feedback/ clarification may write to [query@motilaloswal.com](mailto:query@motilaloswal.com). In case of grievances for any of the services rendered by Motilal Oswal Financial Services Limited (MOFSL) write to [grievances@motilaloswal.com](mailto:grievances@motilaloswal.com), for DP to [dp@motilaloswal.com](mailto:dp@motilaloswal.com).